Oncolinx, in conjunction with the National Cancer Institute is developing the next generation of targeted cancer therapies: antibody-drug conjugates (ADCs). Oncolinx ADCs carry a patented, immune-activating drug payload called the Azonafide directly, and exclusively, to cancer cells, and not healthy cells, thereby avoiding many of the adverse side-effects of chemotherapy.
Each year, the 43North business competition awards $5 million in cash prizes and services to some of the best and brightest entrepreneurs and startups from around the globe. Awards include a one $1 million grand prize, six $500,000 prizes and four $250,000 prizes.
43North is part of New York Governor Andrew Cuomo’s Buffalo Billion initiative, which is driving new economic opportunities...
